Bristol-Myers keen to clear out of infection control:
This article was originally published in Clinica
Bristol-Myers Squibb wants to sell the infection and contamination control businesses which are part of its ConvaTec division. The sectors up for sale were part of Bristol-Myers' acquisition of Calgon Vestal Laboratories last year.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.